0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global NMDA Receptor Antagonist Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-26P12399
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global NMDA Receptor Antagonist Market Research Report 2022
BUY CHAPTERS

Global NMDA Receptor Antagonist Market Research Report 2025

Code: QYRE-Auto-26P12399
Report
March 2025
Pages:92
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

NMDA Receptor Antagonist Market

The global market for NMDA Receptor Antagonist was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for NMDA Receptor Antagonist is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for NMDA Receptor Antagonist is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of NMDA Receptor Antagonist include Algernon Pharmaceuticals, Relmada Therapeutics, UCB, Avanir Pharmaceuticals, Axsome Therapeutics, Seelos Therapeutics, PharmaTher, Cessatech, ATAI Life Sciences, Small Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for NMDA Receptor Antagonist, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NMDA Receptor Antagonist.
The NMDA Receptor Antagonist market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global NMDA Receptor Antagonist market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NMDA Receptor Antagonist manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of NMDA Receptor Antagonist Market Report

Report Metric Details
Report Name NMDA Receptor Antagonist Market
Segment by Type
Segment by Application
  • Parkinson's Disease
  • Alzheimer's Disease
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Algernon Pharmaceuticals, Relmada Therapeutics, UCB, Avanir Pharmaceuticals, Axsome Therapeutics, Seelos Therapeutics, PharmaTher, Cessatech, ATAI Life Sciences, Small Pharma, Bexson Biomedical, DemeRx
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of NMDA Receptor Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of NMDA Receptor Antagonist in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the NMDA Receptor Antagonist Market report?

Ans: The main players in the NMDA Receptor Antagonist Market are Algernon Pharmaceuticals, Relmada Therapeutics, UCB, Avanir Pharmaceuticals, Axsome Therapeutics, Seelos Therapeutics, PharmaTher, Cessatech, ATAI Life Sciences, Small Pharma, Bexson Biomedical, DemeRx

What are the Application segmentation covered in the NMDA Receptor Antagonist Market report?

Ans: The Applications covered in the NMDA Receptor Antagonist Market report are Parkinson's Disease, Alzheimer's Disease, Others

What are the Type segmentation covered in the NMDA Receptor Antagonist Market report?

Ans: The Types covered in the NMDA Receptor Antagonist Market report are Vaccine, Monoclonal Antibody

Recommended Reports

Neurodegenerative Disease

Receptor Antagonist Markets

Neurology Drug Therapies

1 NMDA Receptor Antagonist Market Overview
1.1 Product Definition
1.2 NMDA Receptor Antagonist by Type
1.2.1 Global NMDA Receptor Antagonist Market Value Comparison by Type (2024 VS 2031)
1.2.2 Vaccine
1.2.3 Monoclonal Antibody
1.3 NMDA Receptor Antagonist by Application
1.3.1 Global NMDA Receptor Antagonist Market Value by Application (2024 VS 2031)
1.3.2 Parkinson's Disease
1.3.3 Alzheimer's Disease
1.3.4 Others
1.4 Global NMDA Receptor Antagonist Market Size Estimates and Forecasts
1.4.1 Global NMDA Receptor Antagonist Revenue 2020-2031
1.4.2 Global NMDA Receptor Antagonist Sales 2020-2031
1.4.3 Global NMDA Receptor Antagonist Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 NMDA Receptor Antagonist Market Competition by Manufacturers
2.1 Global NMDA Receptor Antagonist Sales Market Share by Manufacturers (2020-2025)
2.2 Global NMDA Receptor Antagonist Revenue Market Share by Manufacturers (2020-2025)
2.3 Global NMDA Receptor Antagonist Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of NMDA Receptor Antagonist, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of NMDA Receptor Antagonist, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of NMDA Receptor Antagonist, Product Type & Application
2.7 Global Key Manufacturers of NMDA Receptor Antagonist, Date of Enter into This Industry
2.8 Global NMDA Receptor Antagonist Market Competitive Situation and Trends
2.8.1 Global NMDA Receptor Antagonist Market Concentration Rate
2.8.2 The Global 5 and 10 Largest NMDA Receptor Antagonist Players Market Share by Revenue
2.8.3 Global NMDA Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global NMDA Receptor Antagonist Market Scenario by Region
3.1 Global NMDA Receptor Antagonist Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global NMDA Receptor Antagonist Sales by Region: 2020-2031
3.2.1 Global NMDA Receptor Antagonist Sales by Region: 2020-2025
3.2.2 Global NMDA Receptor Antagonist Sales by Region: 2026-2031
3.3 Global NMDA Receptor Antagonist Revenue by Region: 2020-2031
3.3.1 Global NMDA Receptor Antagonist Revenue by Region: 2020-2025
3.3.2 Global NMDA Receptor Antagonist Revenue by Region: 2026-2031
3.4 North America NMDA Receptor Antagonist Market Facts & Figures by Country
3.4.1 North America NMDA Receptor Antagonist Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America NMDA Receptor Antagonist Sales by Country (2020-2031)
3.4.3 North America NMDA Receptor Antagonist Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe NMDA Receptor Antagonist Market Facts & Figures by Country
3.5.1 Europe NMDA Receptor Antagonist Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe NMDA Receptor Antagonist Sales by Country (2020-2031)
3.5.3 Europe NMDA Receptor Antagonist Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific NMDA Receptor Antagonist Market Facts & Figures by Region
3.6.1 Asia Pacific NMDA Receptor Antagonist Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific NMDA Receptor Antagonist Sales by Region (2020-2031)
3.6.3 Asia Pacific NMDA Receptor Antagonist Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America NMDA Receptor Antagonist Market Facts & Figures by Country
3.7.1 Latin America NMDA Receptor Antagonist Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America NMDA Receptor Antagonist Sales by Country (2020-2031)
3.7.3 Latin America NMDA Receptor Antagonist Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa NMDA Receptor Antagonist Market Facts & Figures by Country
3.8.1 Middle East and Africa NMDA Receptor Antagonist Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa NMDA Receptor Antagonist Sales by Country (2020-2031)
3.8.3 Middle East and Africa NMDA Receptor Antagonist Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global NMDA Receptor Antagonist Sales by Type (2020-2031)
4.1.1 Global NMDA Receptor Antagonist Sales by Type (2020-2025)
4.1.2 Global NMDA Receptor Antagonist Sales by Type (2026-2031)
4.1.3 Global NMDA Receptor Antagonist Sales Market Share by Type (2020-2031)
4.2 Global NMDA Receptor Antagonist Revenue by Type (2020-2031)
4.2.1 Global NMDA Receptor Antagonist Revenue by Type (2020-2025)
4.2.2 Global NMDA Receptor Antagonist Revenue by Type (2026-2031)
4.2.3 Global NMDA Receptor Antagonist Revenue Market Share by Type (2020-2031)
4.3 Global NMDA Receptor Antagonist Price by Type (2020-2031)
5 Segment by Application
5.1 Global NMDA Receptor Antagonist Sales by Application (2020-2031)
5.1.1 Global NMDA Receptor Antagonist Sales by Application (2020-2025)
5.1.2 Global NMDA Receptor Antagonist Sales by Application (2026-2031)
5.1.3 Global NMDA Receptor Antagonist Sales Market Share by Application (2020-2031)
5.2 Global NMDA Receptor Antagonist Revenue by Application (2020-2031)
5.2.1 Global NMDA Receptor Antagonist Revenue by Application (2020-2025)
5.2.2 Global NMDA Receptor Antagonist Revenue by Application (2026-2031)
5.2.3 Global NMDA Receptor Antagonist Revenue Market Share by Application (2020-2031)
5.3 Global NMDA Receptor Antagonist Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Algernon Pharmaceuticals
6.1.1 Algernon Pharmaceuticals Company Information
6.1.2 Algernon Pharmaceuticals Description and Business Overview
6.1.3 Algernon Pharmaceuticals NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Algernon Pharmaceuticals NMDA Receptor Antagonist Product Portfolio
6.1.5 Algernon Pharmaceuticals Recent Developments/Updates
6.2 Relmada Therapeutics
6.2.1 Relmada Therapeutics Company Information
6.2.2 Relmada Therapeutics Description and Business Overview
6.2.3 Relmada Therapeutics NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Relmada Therapeutics NMDA Receptor Antagonist Product Portfolio
6.2.5 Relmada Therapeutics Recent Developments/Updates
6.3 UCB
6.3.1 UCB Company Information
6.3.2 UCB Description and Business Overview
6.3.3 UCB NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.3.4 UCB NMDA Receptor Antagonist Product Portfolio
6.3.5 UCB Recent Developments/Updates
6.4 Avanir Pharmaceuticals
6.4.1 Avanir Pharmaceuticals Company Information
6.4.2 Avanir Pharmaceuticals Description and Business Overview
6.4.3 Avanir Pharmaceuticals NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Avanir Pharmaceuticals NMDA Receptor Antagonist Product Portfolio
6.4.5 Avanir Pharmaceuticals Recent Developments/Updates
6.5 Axsome Therapeutics
6.5.1 Axsome Therapeutics Company Information
6.5.2 Axsome Therapeutics Description and Business Overview
6.5.3 Axsome Therapeutics NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Axsome Therapeutics NMDA Receptor Antagonist Product Portfolio
6.5.5 Axsome Therapeutics Recent Developments/Updates
6.6 Seelos Therapeutics
6.6.1 Seelos Therapeutics Company Information
6.6.2 Seelos Therapeutics Description and Business Overview
6.6.3 Seelos Therapeutics NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Seelos Therapeutics NMDA Receptor Antagonist Product Portfolio
6.6.5 Seelos Therapeutics Recent Developments/Updates
6.7 PharmaTher
6.7.1 PharmaTher Company Information
6.7.2 PharmaTher Description and Business Overview
6.7.3 PharmaTher NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.7.4 PharmaTher NMDA Receptor Antagonist Product Portfolio
6.7.5 PharmaTher Recent Developments/Updates
6.8 Cessatech
6.8.1 Cessatech Company Information
6.8.2 Cessatech Description and Business Overview
6.8.3 Cessatech NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Cessatech NMDA Receptor Antagonist Product Portfolio
6.8.5 Cessatech Recent Developments/Updates
6.9 ATAI Life Sciences
6.9.1 ATAI Life Sciences Company Information
6.9.2 ATAI Life Sciences Description and Business Overview
6.9.3 ATAI Life Sciences NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.9.4 ATAI Life Sciences NMDA Receptor Antagonist Product Portfolio
6.9.5 ATAI Life Sciences Recent Developments/Updates
6.10 Small Pharma
6.10.1 Small Pharma Company Information
6.10.2 Small Pharma Description and Business Overview
6.10.3 Small Pharma NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Small Pharma NMDA Receptor Antagonist Product Portfolio
6.10.5 Small Pharma Recent Developments/Updates
6.11 Bexson Biomedical
6.11.1 Bexson Biomedical Company Information
6.11.2 Bexson Biomedical Description and Business Overview
6.11.3 Bexson Biomedical NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Bexson Biomedical NMDA Receptor Antagonist Product Portfolio
6.11.5 Bexson Biomedical Recent Developments/Updates
6.12 DemeRx
6.12.1 DemeRx Company Information
6.12.2 DemeRx Description and Business Overview
6.12.3 DemeRx NMDA Receptor Antagonist Sales, Revenue and Gross Margin (2020-2025)
6.12.4 DemeRx NMDA Receptor Antagonist Product Portfolio
6.12.5 DemeRx Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 NMDA Receptor Antagonist Industry Chain Analysis
7.2 NMDA Receptor Antagonist Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 NMDA Receptor Antagonist Production Mode & Process Analysis
7.4 NMDA Receptor Antagonist Sales and Marketing
7.4.1 NMDA Receptor Antagonist Sales Channels
7.4.2 NMDA Receptor Antagonist Distributors
7.5 NMDA Receptor Antagonist Customer Analysis
8 NMDA Receptor Antagonist Market Dynamics
8.1 NMDA Receptor Antagonist Industry Trends
8.2 NMDA Receptor Antagonist Market Drivers
8.3 NMDA Receptor Antagonist Market Challenges
8.4 NMDA Receptor Antagonist Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global NMDA Receptor Antagonist Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global NMDA Receptor Antagonist Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global NMDA Receptor Antagonist Market Competitive Situation by Manufacturers in 2024
 Table 4. Global NMDA Receptor Antagonist Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global NMDA Receptor Antagonist Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global NMDA Receptor Antagonist Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global NMDA Receptor Antagonist Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market NMDA Receptor Antagonist Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of NMDA Receptor Antagonist, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of NMDA Receptor Antagonist, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of NMDA Receptor Antagonist, Product Type & Application
 Table 12. Global Key Manufacturers of NMDA Receptor Antagonist, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global NMDA Receptor Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NMDA Receptor Antagonist as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global NMDA Receptor Antagonist Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global NMDA Receptor Antagonist Sales by Region (2020-2025) & (K Units)
 Table 18. Global NMDA Receptor Antagonist Sales Market Share by Region (2020-2025)
 Table 19. Global NMDA Receptor Antagonist Sales by Region (2026-2031) & (K Units)
 Table 20. Global NMDA Receptor Antagonist Sales Market Share by Region (2026-2031)
 Table 21. Global NMDA Receptor Antagonist Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global NMDA Receptor Antagonist Revenue Market Share by Region (2020-2025)
 Table 23. Global NMDA Receptor Antagonist Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global NMDA Receptor Antagonist Revenue Market Share by Region (2026-2031)
 Table 25. North America NMDA Receptor Antagonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America NMDA Receptor Antagonist Sales by Country (2020-2025) & (K Units)
 Table 27. North America NMDA Receptor Antagonist Sales by Country (2026-2031) & (K Units)
 Table 28. North America NMDA Receptor Antagonist Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America NMDA Receptor Antagonist Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe NMDA Receptor Antagonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe NMDA Receptor Antagonist Sales by Country (2020-2025) & (K Units)
 Table 32. Europe NMDA Receptor Antagonist Sales by Country (2026-2031) & (K Units)
 Table 33. Europe NMDA Receptor Antagonist Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe NMDA Receptor Antagonist Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific NMDA Receptor Antagonist Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific NMDA Receptor Antagonist Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific NMDA Receptor Antagonist Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific NMDA Receptor Antagonist Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific NMDA Receptor Antagonist Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America NMDA Receptor Antagonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America NMDA Receptor Antagonist Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America NMDA Receptor Antagonist Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America NMDA Receptor Antagonist Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America NMDA Receptor Antagonist Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa NMDA Receptor Antagonist Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa NMDA Receptor Antagonist Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa NMDA Receptor Antagonist Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa NMDA Receptor Antagonist Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa NMDA Receptor Antagonist Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global NMDA Receptor Antagonist Sales (K Units) by Type (2020-2025)
 Table 51. Global NMDA Receptor Antagonist Sales (K Units) by Type (2026-2031)
 Table 52. Global NMDA Receptor Antagonist Sales Market Share by Type (2020-2025)
 Table 53. Global NMDA Receptor Antagonist Sales Market Share by Type (2026-2031)
 Table 54. Global NMDA Receptor Antagonist Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global NMDA Receptor Antagonist Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global NMDA Receptor Antagonist Revenue Market Share by Type (2020-2025)
 Table 57. Global NMDA Receptor Antagonist Revenue Market Share by Type (2026-2031)
 Table 58. Global NMDA Receptor Antagonist Price (US$/Unit) by Type (2020-2025)
 Table 59. Global NMDA Receptor Antagonist Price (US$/Unit) by Type (2026-2031)
 Table 60. Global NMDA Receptor Antagonist Sales (K Units) by Application (2020-2025)
 Table 61. Global NMDA Receptor Antagonist Sales (K Units) by Application (2026-2031)
 Table 62. Global NMDA Receptor Antagonist Sales Market Share by Application (2020-2025)
 Table 63. Global NMDA Receptor Antagonist Sales Market Share by Application (2026-2031)
 Table 64. Global NMDA Receptor Antagonist Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global NMDA Receptor Antagonist Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global NMDA Receptor Antagonist Revenue Market Share by Application (2020-2025)
 Table 67. Global NMDA Receptor Antagonist Revenue Market Share by Application (2026-2031)
 Table 68. Global NMDA Receptor Antagonist Price (US$/Unit) by Application (2020-2025)
 Table 69. Global NMDA Receptor Antagonist Price (US$/Unit) by Application (2026-2031)
 Table 70. Algernon Pharmaceuticals Company Information
 Table 71. Algernon Pharmaceuticals Description and Business Overview
 Table 72. Algernon Pharmaceuticals NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Algernon Pharmaceuticals NMDA Receptor Antagonist Product
 Table 74. Algernon Pharmaceuticals Recent Developments/Updates
 Table 75. Relmada Therapeutics Company Information
 Table 76. Relmada Therapeutics Description and Business Overview
 Table 77. Relmada Therapeutics NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Relmada Therapeutics NMDA Receptor Antagonist Product
 Table 79. Relmada Therapeutics Recent Developments/Updates
 Table 80. UCB Company Information
 Table 81. UCB Description and Business Overview
 Table 82. UCB NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. UCB NMDA Receptor Antagonist Product
 Table 84. UCB Recent Developments/Updates
 Table 85. Avanir Pharmaceuticals Company Information
 Table 86. Avanir Pharmaceuticals Description and Business Overview
 Table 87. Avanir Pharmaceuticals NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Avanir Pharmaceuticals NMDA Receptor Antagonist Product
 Table 89. Avanir Pharmaceuticals Recent Developments/Updates
 Table 90. Axsome Therapeutics Company Information
 Table 91. Axsome Therapeutics Description and Business Overview
 Table 92. Axsome Therapeutics NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Axsome Therapeutics NMDA Receptor Antagonist Product
 Table 94. Axsome Therapeutics Recent Developments/Updates
 Table 95. Seelos Therapeutics Company Information
 Table 96. Seelos Therapeutics Description and Business Overview
 Table 97. Seelos Therapeutics NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Seelos Therapeutics NMDA Receptor Antagonist Product
 Table 99. Seelos Therapeutics Recent Developments/Updates
 Table 100. PharmaTher Company Information
 Table 101. PharmaTher Description and Business Overview
 Table 102. PharmaTher NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. PharmaTher NMDA Receptor Antagonist Product
 Table 104. PharmaTher Recent Developments/Updates
 Table 105. Cessatech Company Information
 Table 106. Cessatech Description and Business Overview
 Table 107. Cessatech NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Cessatech NMDA Receptor Antagonist Product
 Table 109. Cessatech Recent Developments/Updates
 Table 110. ATAI Life Sciences Company Information
 Table 111. ATAI Life Sciences Description and Business Overview
 Table 112. ATAI Life Sciences NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. ATAI Life Sciences NMDA Receptor Antagonist Product
 Table 114. ATAI Life Sciences Recent Developments/Updates
 Table 115. Small Pharma Company Information
 Table 116. Small Pharma Description and Business Overview
 Table 117. Small Pharma NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Small Pharma NMDA Receptor Antagonist Product
 Table 119. Small Pharma Recent Developments/Updates
 Table 120. Bexson Biomedical Company Information
 Table 121. Bexson Biomedical Description and Business Overview
 Table 122. Bexson Biomedical NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Bexson Biomedical NMDA Receptor Antagonist Product
 Table 124. Bexson Biomedical Recent Developments/Updates
 Table 125. DemeRx Company Information
 Table 126. DemeRx Description and Business Overview
 Table 127. DemeRx NMDA Receptor Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. DemeRx NMDA Receptor Antagonist Product
 Table 129. DemeRx Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. NMDA Receptor Antagonist Distributors List
 Table 133. NMDA Receptor Antagonist Customers List
 Table 134. NMDA Receptor Antagonist Market Trends
 Table 135. NMDA Receptor Antagonist Market Drivers
 Table 136. NMDA Receptor Antagonist Market Challenges
 Table 137. NMDA Receptor Antagonist Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of NMDA Receptor Antagonist
 Figure 2. Global NMDA Receptor Antagonist Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global NMDA Receptor Antagonist Market Share by Type: 2024 & 2031
 Figure 4. Vaccine Product Picture
 Figure 5. Monoclonal Antibody Product Picture
 Figure 6. Global NMDA Receptor Antagonist Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global NMDA Receptor Antagonist Market Share by Application: 2024 & 2031
 Figure 8. Parkinson's Disease
 Figure 9. Alzheimer's Disease
 Figure 10. Others
 Figure 11. Global NMDA Receptor Antagonist Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global NMDA Receptor Antagonist Market Size (2020-2031) & (US$ Million)
 Figure 13. Global NMDA Receptor Antagonist Sales (2020-2031) & (K Units)
 Figure 14. Global NMDA Receptor Antagonist Average Price (US$/Unit) & (2020-2031)
 Figure 15. NMDA Receptor Antagonist Report Years Considered
 Figure 16. NMDA Receptor Antagonist Sales Share by Manufacturers in 2024
 Figure 17. Global NMDA Receptor Antagonist Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest NMDA Receptor Antagonist Players: Market Share by Revenue in NMDA Receptor Antagonist in 2024
 Figure 19. NMDA Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global NMDA Receptor Antagonist Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America NMDA Receptor Antagonist Sales Market Share by Country (2020-2031)
 Figure 22. North America NMDA Receptor Antagonist Revenue Market Share by Country (2020-2031)
 Figure 23. United States NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe NMDA Receptor Antagonist Sales Market Share by Country (2020-2031)
 Figure 26. Europe NMDA Receptor Antagonist Revenue Market Share by Country (2020-2031)
 Figure 27. Germany NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific NMDA Receptor Antagonist Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific NMDA Receptor Antagonist Revenue Market Share by Region (2020-2031)
 Figure 34. China NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Latin America NMDA Receptor Antagonist Sales Market Share by Country (2020-2031)
 Figure 42. Latin America NMDA Receptor Antagonist Revenue Market Share by Country (2020-2031)
 Figure 43. Mexico NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Brazil NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Argentina NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa NMDA Receptor Antagonist Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa NMDA Receptor Antagonist Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE NMDA Receptor Antagonist Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of NMDA Receptor Antagonist by Type (2020-2031)
 Figure 52. Global Revenue Market Share of NMDA Receptor Antagonist by Type (2020-2031)
 Figure 53. Global NMDA Receptor Antagonist Price (US$/Unit) by Type (2020-2031)
 Figure 54. Global Sales Market Share of NMDA Receptor Antagonist by Application (2020-2031)
 Figure 55. Global Revenue Market Share of NMDA Receptor Antagonist by Application (2020-2031)
 Figure 56. Global NMDA Receptor Antagonist Price (US$/Unit) by Application (2020-2031)
 Figure 57. NMDA Receptor Antagonist Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Leap India